PHILADELPHIA, Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a le ...

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out o ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines over the summer of 2025 [1] Summary by Sections Lawsuit Details - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., aims to represent investors who acquired the company's securities between February 21, 2025, and August 28, 2025 [3] - The complaint alleges that the company and its executives made false and misleading statements about the business, inflating the company's valuation before the truth was revealed [3] Core Allegations - The lawsuit claims that Telix violated the Securities Exchange Act of 1934 by failing to disclose: - Overstated therapeutic progress regarding prostate cancer therapeutic candidates TLX591 and TLX592 [4] - Misrepresentation of the stability, quality, and regulatory compliance of its third-party supply chain and manufacturing partners [5] Regulatory Events Impacting Stock - Two key events led to a significant decline in Telix's American Depositary Shares (ADSs): - **SEC Subpoena (July 22, 2025)**: The company disclosed receiving a subpoena from the SEC, leading to a stock price drop of over 13% in two trading sessions [6] - **FDA Rejection (August 28, 2025)**: Telix received a Complete Response Letter from the FDA for TLX250-CDx, resulting in a further decline of more than 21% in two trading sessions [7][8] Class Action and Investigation - The class action litigation is filed in the U.S. District Court for the Southern District of Indiana, seeking damages for investors who suffered losses due to the alleged securities fraud [10] - Hagens Berman is investigating the claims, focusing on discrepancies between the company's assurances and the regulatory revelations [11]

Accessibility StatementSkip Navigation NEW YORK, Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TLX during ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025, to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 28, 2025 5:26 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 28, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both da ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, particularly following critical disclosures regarding its manufacturing and supply chain processes [1][4]. Allegations and Events - The lawsuit alleges that Telix and its executives made false and misleading statements about the company's business, inflating its valuation before the truth was revealed [2][3]. - Key allegations include overstated therapeutic progress for prostate cancer candidates TLX591 and TLX592, and misrepresentation of the stability and regulatory compliance of its third-party supply chain [5]. - The lawsuit identifies two major events that led to a sharp decline in Telix's stock price: 1. A subpoena from the SEC on July 22, 2025, which caused a more than 13% drop in stock price over two trading sessions [5]. 2. A Complete Response Letter from the FDA on August 28, 2025, rejecting the Biologics License Application for TLX250-CDx, leading to a further decline of over 21% in stock price [5][4]. Investigation - Hagens Berman is investigating the claims against Telix, focusing on discrepancies between the company's assurances and the regulatory revelations that followed [6].

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telix Pharmaceuticals Limited (NASDAQ:TLX) and Firefly Aerospace Inc. (NASDAQ:FLY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Telix Pharmaceuticals Limited (NASDAQ:TLX) Class ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a class action lawsuit due to allegations of misleading investors regarding its prostate cancer therapeutic candidates, TLX591 and TLX592, during the class period from February 21, 2025, to August 28, 2025 [1][2]. Summary by Sections Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1]. Class Action Details - A class action was filed on behalf of investors who purchased Telix securities during the specified class period, alleging that the company materially overstated the progress and quality of its prostate cancer therapeutic candidates and supply chain [1][2]. Allegations and Developments - The complaint states that on July 22, 2025, Telix disclosed an SEC investigation into its disclosures regarding the development of TLX591 and TLX592 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data for the drug product used in the phase 3 clinical trial [3]. - The CRL also indicated that notices of deficiency were issued to Telix's third-party manufacturing and supply chain partners, which must be addressed before resubmitting the Biologics License Application (BLA) [3]. Investor Actions - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by January 9, 2026 [4]. - Investors can remain absent class members if they choose not to participate in the case [4]. Legal Representation - Robbins LLP is leading the class action, emphasizing that all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, with allegations of misleading statements regarding its business operations and therapeutic candidates [1][2][3]. Allegations - The lawsuit claims that Telix overstated the developmental progress and commercial prospects of its prostate cancer therapeutic candidates, specifically TLX591 and TLX592 [3]. - It is alleged that the company misrepresented the stability, quality, and regulatory compliance of its third-party supply chain and manufacturing partners, which were critical to its regulatory applications [4]. Regulatory Events Impacting Stock - The first significant stock decline occurred after Telix disclosed receiving a subpoena from the SEC on July 22, 2025, leading to a more than 13% drop in the price of Telix's American Depositary Shares (ADSs) over two trading sessions [5]. - A more severe decline followed the announcement of a Complete Response Letter (CRL) from the FDA on August 28, 2025, regarding TLX250-CDx (Zircaix), which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, resulting in a further decline of over 21% in the stock price [6][7]. Investigation - Hagens Berman is actively investigating the claims against Telix, focusing on the discrepancies between the company's long-term assurances and the regulatory revelations that followed [8].